- Povorcitinib, an oral JAK1 inhibitor by Incyte, showed positive results in phase 3 trials for hidradenitis suppurativa.
- Efficacy outcomes were slightly lower than those observed in prior studies.
- The drug may offer an alternative for patients who do not respond to or are not eligible for biologic drugs.
- Incyte plans to seek regulatory approval for povorcitinib in late 2025 or early 2026.
- Incyte anticipates deeper responses with continued dosing and is extending the trial to assess outcomes over 54 weeks.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
